JP2022514903A5 - - Google Patents

Info

Publication number
JP2022514903A5
JP2022514903A5 JP2021535978A JP2021535978A JP2022514903A5 JP 2022514903 A5 JP2022514903 A5 JP 2022514903A5 JP 2021535978 A JP2021535978 A JP 2021535978A JP 2021535978 A JP2021535978 A JP 2021535978A JP 2022514903 A5 JP2022514903 A5 JP 2022514903A5
Authority
JP
Japan
Prior art keywords
seq
cdr
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535978A
Other languages
English (en)
Japanese (ja)
Other versions
JP7548907B2 (ja
JP2022514903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/061058 external-priority patent/WO2020128927A1/en
Publication of JP2022514903A publication Critical patent/JP2022514903A/ja
Publication of JP2022514903A5 publication Critical patent/JP2022514903A5/ja
Application granted granted Critical
Publication of JP7548907B2 publication Critical patent/JP7548907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535978A 2018-12-20 2019-12-19 Fn14抗体及びその使用 Active JP7548907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782912P 2018-12-20 2018-12-20
US62/782,912 2018-12-20
PCT/IB2019/061058 WO2020128927A1 (en) 2018-12-20 2019-12-19 Fn14 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2022514903A JP2022514903A (ja) 2022-02-16
JP2022514903A5 true JP2022514903A5 (https=) 2022-12-26
JP7548907B2 JP7548907B2 (ja) 2024-09-10

Family

ID=69159866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535978A Active JP7548907B2 (ja) 2018-12-20 2019-12-19 Fn14抗体及びその使用

Country Status (7)

Country Link
US (1) US12234292B2 (https=)
EP (1) EP3898687A1 (https=)
JP (1) JP7548907B2 (https=)
AU (1) AU2019402163A1 (https=)
CA (1) CA3124356A1 (https=)
TW (1) TW202031684A (https=)
WO (1) WO2020128927A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240092916A1 (en) * 2021-01-13 2024-03-21 Astellas Pharma Inc. MULTISPECIFIC ANTIBODY BINDING TO ActRIIA, ActRIIB, AND Fn14
WO2022155705A1 (en) * 2021-01-20 2022-07-28 La Trobe University Humanized fn14-binding proteins and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX2010012324A (es) 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
AU2010231575B2 (en) * 2009-03-30 2013-09-12 Edimer Biotech S.A. Preparation of isolated agonist anti-EDAR monoclonal antibodies
HK1198832A1 (en) 2011-08-23 2015-06-12 Transbio Ltd Fn14 binding proteins and uses thereof
US11045428B2 (en) * 2014-11-21 2021-06-29 University Of Maryland, Baltimore Decreased adhesivity receptor-targeted nanoparticles for Fn14-positive tumors
MY204672A (en) 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody

Similar Documents

Publication Publication Date Title
JP7504664B2 (ja) 二重特異性抗体
AU2013276131B2 (en) Improved antagonist antibodies against GDF-8 and uses therefor
EP4198055A1 (en) Antibody of il-11 and use thereof
WO2013039954A1 (en) Anti-gitr antibodies
JP2015511931A5 (https=)
JP2011518857A5 (https=)
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2022514903A5 (https=)
JP2021515039A5 (https=)
JP2025500796A (ja) 抗変異体カルレチクリン(calr)抗体及びその使用
TW202430247A (zh) 肌肉生長抑制素活化之選擇性及強效抑制劑
JP6755513B2 (ja) 抗スクレロスチン抗体、その抗原結合フラグメントおよびその医薬用途
CN115594762A (zh) 一种铁蛋白重链抗体及其用途
TWI834254B (zh) α-烯醇酶拮抗劑治療纖維化疾病之用途
CN110139661A (zh) Igfb3及其受体相关疾病的治疗
ES2926019T3 (es) Estructuras de anticuerpos para reducir la agregación de anticuerpos multiespecíficos
US9567390B2 (en) Humanized high affinity recombinant antibody against Hepatitis B surface antigen
CN116425871B (zh) 抗新冠病毒s蛋白人源化抗体及其应用
WO2024054678A2 (en) Antibodies against fentanyl and analogs and methods of use thereof
CN115925934B (zh) 一种稳定性提高的人源化单克隆抗体及其应用
JP2024177124A (ja) 抗変異体カルレチクリン(calr)抗体及びその使用
WO2025226637A1 (en) Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
WO2024111576A1 (ja) 抗gpa33抗体及びその利用
BR112016021083B1 (pt) Polipeptídeo de fusão bi-específico, composição farmacêutica e seus usos